Vor Biopharma (NASDAQ:VOR) Shares Down 5% – Here’s Why

Vor Biopharma Inc. (NASDAQ:VOR) fell 5% during mid-day trading on Monday . The stock traded as low as $17.26 and last traded at $17.18. 143,547 shares were traded during trading, a decline of 87% from the average daily volume of 1,096,618 shares. The stock had previously closed at $18.09.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the stock. Wall Street Zen downgraded shares of Vor Biopharma from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Wedbush upped their price objective on Vor Biopharma from $15.00 to $18.00 and gave the stock a “neutral” rating in a research note on Thursday, May 14th. HC Wainwright reiterated a “buy” rating and set a $31.00 target price on shares of Vor Biopharma in a research report on Monday, May 18th. Jefferies Financial Group upgraded Vor Biopharma to a “strong-buy” rating in a research report on Thursday, April 30th. Finally, Weiss Ratings raised Vor Biopharma from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, June 30th. Two research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Vor Biopharma currently has a consensus rating of “Moderate Buy” and a consensus price target of $42.25.

Vor Biopharma Stock Down 5.1%

The firm’s fifty day moving average is $15.94 and its two-hundred day moving average is $15.02.

Vor Biopharma (NASDAQ:VOR) last issued its quarterly earnings results on Monday, March 30th. The company reported $307.61 earnings per share (EPS) for the quarter. On average, analysts expect that Vor Biopharma Inc. will post -2.51 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Ra Capital Management, L.P. sold 165,150 shares of the stock in a transaction dated Wednesday, April 22nd. The stock was sold at an average price of $15.77, for a total transaction of $2,604,415.50. Following the completion of the sale, the director owned 2,402,095 shares in the company, valued at approximately $37,881,038.15. This trade represents a 6.43% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.27% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. China Universal Asset Management Co. Ltd. purchased a new stake in Vor Biopharma during the 4th quarter valued at approximately $36,000. Goldman Sachs Group Inc. grew its stake in Vor Biopharma by 218.2% during the first quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company’s stock valued at $61,000 after acquiring an additional 58,247 shares in the last quarter. XTX Topco Ltd bought a new stake in Vor Biopharma in the 2nd quarter valued at $66,000. Chung Wu Investment Group LLC bought a new stake in Vor Biopharma in the 4th quarter valued at $109,000. Finally, Susquehanna Portfolio Strategies LLC purchased a new stake in Vor Biopharma in the 4th quarter worth $134,000. 97.29% of the stock is currently owned by institutional investors.

Vor Biopharma Company Profile

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).